When combined with cytokine-preactivated peripheral blood or cord blood NK cells, AFM13 induced CAR-like activity with strong anti-tumor effects and improved survival outcomes in CD30+ lymphoma xenograft models [197]. The gene discussed is TNFRSF8; the disease is lymphoma.